A study [21] found that administering abemaciclib, which is a CDK4/6 inhibitor in the early stage of HR-positive/HER2-negative (HR+/HER2−) breast cancer, rather than waiting until patients develop metastatic disease, was a cost-effective treatment strategy. The gene discussed is CDK4; the disease is breast cancer.